Drug

Spartalizumab

In clinical development

ClassProgrammed cell death protein 1 antagonistEmerging researchLate-stage development

RxNorm2169893 ChEMBLCHEMBL4297831UNIIQOG25L6Z8Z

Research papers

Active clinical trials

Programmed cell death protein 1

Primary target

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Pilot Study of Neoadjuvant Combination Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1 Trial)

Clinical trial2026-03-05Completed · ClinicalTrials.gov

An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Clinical trial2026-01-07Results expected Q1 2028 · ClinicalTrials.gov

Phase II Trial to Evaluate the Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma

Clinical trial2025-10-01Suspended · ClinicalTrials.gov

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff

Clinical trial2025-09-30Primary completion · ClinicalTrials.gov

A Phase Ib/II Trial of Siltuximab and Spartalizumab in Metastatic Pancreatic Cancer

Clinical trial2025-08-22Results posted · ClinicalTrials.gov

A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal Cancer

Clinical trial2024-09-25Terminated · ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Clinical trial2024-08-21Terminated · ClinicalTrials.gov

A Phase II, Open Label, Randomized, Parallel Arm Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy Gemcitabine/Nab-paclitaxel, and Gemcitabine/Nab-paclitaxel Alone in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Clinical trial2024-05-02Terminated · ClinicalTrials.gov

A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Combinations in Adult Patients With Myelofibrosis

Clinical trial2024-04-11Withdrawn · ClinicalTrials.gov

A Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Clinical trial2024-01-15Terminated · ClinicalTrials.gov

Ribociclib and Spartalizumab for Head and Neck Squamous Cell Carcinoma, a Phase I Study With Expansion Cohort (RISE-HN)

Clinical trial2024-01-01Primary completion · ClinicalTrials.gov

Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.

Research2021-04-21Clinical cancer research : an official journal of the American Association for Cancer Research

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Spartalizumab

RxNorm CUI

2169893

ChEMBL ID

CHEMBL4297831

UNII

QOG25L6Z8Z

Primary mechanism

Programmed cell death protein 1 antagonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Programmed cell death protein 1

PDCD1 · Q15116

ANTAGONISTProgrammed cell death protein 1 antagonist

Clinical trials

19 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 19

Early Phase 11Phase 17Phase 1 / 22Phase 28Phase 31

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

TerminatedPH IIINovartis Pharmaceuticalsn=5682024

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Pilot Study of Neoadjuvant Combination Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1 Trial)

CompletedPH IColumbia Universityn=172026

A Phase Ib/II Trial of Siltuximab and Spartalizumab in Metastatic Pancreatic Cancer

CompletedPH I/IIEmory Universityn=352023

A Phase Ib/II, Open-label, Multi-center Study of INC280 in Combination With PDR001 or PDR001 Single Agent in Advanced Hepatocellular Carcinoma.

CompletedPH I/IINovartis Pharmaceuticalsn=892021

A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment

CompletedPH IINovartis Pharmaceuticalsn=1222021

Phase II Multicenter Randomized Two-arm Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Pretreated Adult Patients With EGFR Wild-type ALK Rearrangement Negative Advanced/Metastatic Non-small Cell Lung Cancer

CompletedPH IINovartis Pharmaceuticalsn=182020

Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer

CompletedPH INovartis Pharmaceuticalsn=102019

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2021 · 285 cites

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Sabatolimab

Studied across the same disease area as Spartalizumab in the shared literature.

1 shared disease1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials